July 10 Company Quick Takes: I-Mab licenses MacroGenics mAb; plus Mirati-Novartis, Jazz-Redx, Sanofi, Horizon and more

I-Mab gains China rights to enoblituzumab

I-Mab Biopharma (Shanghai, China) gained exclusive rights to enoblituzumab from MacroGenics Inc. (NASDAQ:MGNX) in China, Hong Kong, Macao and Taiwan for $15 million up front. MacroGenics is eligible for $135 million in development and regulatory milestones, plus tiered double-digit royalties. MacroGenics plans to begin a Phase II trial this year of the Fc-optimized mAb against B7-H3 in combination with PD-1 inhibitor MGA012 (also known as INCMGA0012) to treat first-line head and neck cancer; I-Mab will lead regional studies of enoblituzumab...